The FDA on June 3, 2025, approved NUBEQA® for metastatic Castration-Sensitive Prostate Cancer (mCSPC). The FDA previously approved NUBEQA® in combination with Docetaxel for mCSPC. NUBEQA® is a product of Bayer Healthcare Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
